title: Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.
abstract: The safety and efficacy of 0.1% tacrolimus ointment for the treatment of psoriasis on the face, intertriginous areas, or both were evaluated in an open-label, clinical trial of 21 patients with psoriasis. Patients applied 0.1% tacrolimus ointment twice daily for 8 weeks. Efficacy was assessed through the investigator's evaluation of the individual signs and symptoms of psoriasis, and the physician's global evaluation of change in disease status. Assessments of cutaneous atrophy and other adverse events were made throughout the study to evaluate the safety of tacrolimus ointment. A total of 21 patients were enrolled in the study; 21 patients at least 18 years of age received study medication. Statistically significant improvement in the physician's assessment of the individual signs and symptoms was observed during the study. A total of 81% of patients (17 of 21) experienced complete clearance at day 57 (end of treatment). Only 2 patients reported adverse events, which were limited to itching and the feeling of warmth at the application site. None of the patients had atrophy, telangiectasia, or striae develop during the study. In summary, tacrolimus 0.1% ointment may be a safe and effective treatment option for patients with psoriasis on the face, intertriginous areas, or both.
authors.affiliation: Mount Sinai School of Medicine, Department of Dermatology, New York, NY 10029, USA.
authors.forename: Amy Krupnick
authors.initials: AK
authors.lastname: Freeman
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Linowski
authors.forename: Christopher
authors.initials: C
authors.lastname: Brady
authors.forename: Leah
authors.initials: L
authors.lastname: Lind
authors.forename: Paul
authors.initials: P
authors.lastname: Vanveldhuisen
authors.forename: Giselle
authors.initials: G
authors.lastname: Singer
authors.forename: Mark
authors.initials: M
authors.lastname: Lebwohl
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus